The role of somatostatin analogues in the treatment of neuroendocrine tumours
Simona Grozinsky-Glasberg, Ashley B. Grossman, Márta Korbonits

To cite this version:

HAL Id: hal-00531955
https://hal.archives-ouvertes.fr/hal-00531955
Submitted on 4 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
THE ROLE OF SOMATOSTATIN ANALOGUES IN THE TREATMENT OF NEUROENDOCRINE TUMOURS

Simona Grozinsky-Glasberg¹,², Ashley B. Grossman¹ and Márta Korbonits¹

¹Department of Endocrinology, William Harvey Research Institute, Barts and the London, Queen Mary School of Medicine, University of London, EC1M 6BQ, UK, and

²Department of Endocrinology, Beilinson Hospital, Rabin Medical Center, and Sackler Faculty of Medicine, Tel Aviv, 49100, Israel.

Key words: Somatostatin, Octreotide, and Neuroendocrine Tumours

Address all correspondence to:
Márta Korbonits MD, PhD
Reader in Endocrine Research
Department of Endocrinology
William Harvey Research Institute
Barts and the London Medical School
Charterhouse Square
London EC1M 6BQ

Tel +44 20 7882 6238
Fax +44 20 7882 6197
email: m.korbonits@qmul.ac.uk
Abstract

Neuroendocrine tumours belong to a heterogeneous family of neoplasms, originating in endocrine glands (such as the pituitary, parathyroid or the neuroendocrine adrenal glands), in endocrine islets (within the thyroid or pancreas) as well as in endocrine cells dispersed between exocrine cells throughout the digestive or respiratory tracts. The clinical behaviour of neuroendocrine tumours is variable; they may be functioning or not functioning, ranging from well-differentiated slow growing neuroendocrine tumours to poorly-differentiated neuroendocrine tumours, which are highly aggressive malignant tumours. The development of somatostatin analogues as important diagnostic and treatment tools have revolutionised the clinical management of patients with neuroendocrine tumours. However, although symptomatic relief and stabilisation of tumour growth for various periods of time are observed in many patients treated with somatostatin analogues, tumour regression is rare. Development of new somatostatin analogues and new drug combination therapies should further improve the clinical management of these patients.
Introduction

Neuroendocrine tumours (NETs) comprise a family of neoplasms that present with a fascinating range of morphologic, functional and behavioural characteristics (Oberg, 2005).

The traditional classification of NETs include tumours originating in the adrenal medulla and sympathetic ganglia, C cells of the thyroid gland, islets of the pancreas as well as in the endocrine cells distributed throughout the digestive or the respiratory tracts (Rindi et al., 2000; Solcia et al., 1999). NETs were first described in 1888 by Otto Lubarsch who found multiple ileal tumours in two patients at autopsy. It was then 15 years later that Oberndorfer introduced the term carcinoid for ileal tumours that presented a more benign disease course than that of colon carcinomas (Modlin et al., 2004). Subsequently, endocrine tumours of the gastrointestinal tract as well as lesions from other organs were called carcinoids, and were classified on the basis of the anatomic site of origin into foregut carcinoids (lung, thymus, stomach, pancreas, duodenum, upper jejunum), midgut carcinoids (lower jejunum, ileum, appendix, proximal colon) and hindgut carcinoids (transverse colon, sigmoid and rectum) (Caplin et al., 1998; Ganim & Norton, 2000; Vinik et al., 1989). NETs originating from the gastrointestinal tract and the pancreas are also called gastroenteropancreatic neuroendocrine tumours (GEP NETs). According to the latest World Health Organization (WHO) classification (Solcia et al., 2000), which is based on tumour histology, tumour size and the presence or absence of local/distant metastases, NETs should be stratified into (a) well-differentiated neuroendocrine tumours, (b) well-differentiated endocrine carcinomas, (c) poorly differentiated neuroendocrine carcinomas and (d) mixed exocrine-endocrine carcinomas. The great majority of NETs are relatively slow growing (well-differentiated), while some of them may
present with more aggressive behaviour (poorly differentiated neuroendocrine carcinoma); these latter are fast growing tumours and, therefore, highly malignant. The well-differentiated NETs have the important ability to uptake neuroamines and to express specific receptors on their cells membranes, such as somatostatin receptors (SSTR), although not in all cases; this characteristic may be of great value for the localisation and the treatment of these tumours (Kaltsas et al., 2001). While a relatively wide variety of therapeutic options are available for treating these patients (e.g., surgery, somatostatin analogue therapy, interferon-α, peptide receptor radiotherapy, chemotherapy, chemo-embolisation, etc.), few are curative and most treatments are palliative. It is unclear as to why certain of these tumours remain localised and respond well to therapy, while others present with inoperable metastatic disease and severe hormonal symptoms (Eriksson & Oberg, 1999). Therefore, successful treatment of these diseases necessitates a multidisciplinary approach in order to control symptoms, to stabilise or prevent further growth and, rarely, to achieve cure.

The response of the tumour to different therapeutic options may be defined, according to established WHO criteria, as: 1) complete response (complete regression of all clinical, radiological and hormonal evidence of tumour); 2) partial response (a 50% or greater reduction in all measurable tumour, clinical symptoms and hormonal levels, with no appearance of new lesions); 3) stable disease (less than 50% reduction or no greater than 25% increase in tumour size, clinical symptoms and hormonal measurements) and 4) progression (appearance of new lesions, or an increase of 25% or more in tumour size, and clinical/hormonal deterioration) (Arnold et al., 2000).
In this review we will summarise the literature regarding the role of somatostatin analogues in the diagnosis and mostly in the treatment of gastroenteropancreatic (GEP) NETs and of other NETs, including NETs originating from parafollicular C cells of the thyroid, bronchial carcinoids, thymic carcinoids, ovarian carcinoid tumours and phaeochromocytomas/paragangliomas.

I. The role of somatostatin in the diagnostic and the treatment of gastroenteropancreatic neuroendocrine tumours (GEP NETs)

Overall, GEP NETs constitute approximately 2% of all malignant tumours of the gastrointestinal system (Moertel, 1987). Midgut carcinoids, which originate from serotonin-producing enterochromaffin cells, constitute the largest group, while the second largest group includes endocrine pancreatic tumours. Pancreatic tumours may be subdivided depending on the predominant hormone production and the clinical picture. Patients may have symptoms for many years before the diagnosis is made and therefore, in order to diagnose these tumours, the index of suspicion must be high.

During the last decade, the diagnostic and therapeutic approach of endocrine GEP tumours has considerably improved, mainly due to better imaging techniques with CT, MRI, PET and somatostatin analogue-based imaging methods, as well as receptor subtype characterisation and the introduction of long-acting somatostatin analogues.

**Somatostatin receptor imaging of GEP NET**

Somatostatin (somatotropin release-inhibiting hormone (SRIF)) is a peptide hormone present in two natural forms (14 and 28 amino-acids) which bind with high affinity to
5 different subtypes of specific somatostatin receptors (Patel et al., 1990). The very short half life of the natural compound (around 3 minutes) has resulted in the development of synthetic analogues: short-acting analogues (octreotide, lanreotide or vapreotide, which need to be administered subcutaneously several times per day), or long-acting analogues (octreotide long-acting release, LAR, and lanreotide autogel, both with monthly administration) (Heron et al., 1993). Tumours and metastases that express the somatostatin receptor subtypes SSTR2, SSTR3 or SSTR5 can be visualised in vivo using injection of radiolabelled somatostatin analogues (e.g. $^{111}$In-pentetreotide) (de Herder et al., 2006a). SSTR2 and SSTR5 are expressed in about 70%-90% of GEP NET. Except for benign insulinomas in which, due to the lower expression of SSTR2, the sensitivity of the scintigraphy is only about 40-50%, the overall sensitivity of SSTR scintigraphy is high, from 86% to 95% for gut carcinoid tumours to 75%-100% for pancreatic endocrine tumours (Lamberts et al., 2002a; van Eyck et al., 1993).

SSTR scintigraphy has become a very important tool in the accurate staging and treatment of GEP NETs due to its ability to detect tumour sites which are not visualised by conventional imaging methods. It may also help to decide which patients are suitable for surgery, on suitability for treatment with somatostatin analogues (octreotide or lanreotide), or for tumour-targeted radioactive therapy using one of the radiolabelled somatostatin analogues (Janson et al., 1999; Krenning et al., 1999; Kwekkeboom et al., 2005; Lamberts et al., 1990; Lamberts et al., 2002a; Oberg, 2004; van Eyck et al., 1993). Several reviews are available discussing this topic in detail (de Herder & Lamberts, 2002; de Herder et al., 2003; Kaltsas et al., 2005).
The role of somatostatin analogues in the treatment of specific GEP NETs

The somatostatin analogue octreotide has been in clinical use for treatment of NETs since the early 1980s, having both cytotoxic and cytostatic actions; it was shown to influence cell growth and induce apoptosis, particularly at high doses (Garcia et al., 2002).

[A] Somatostatin analogues for the treatment of the endocrine tumours of the gastric mucosa

The enterochromaffin like (ECL) cells originating in the gastric mucosa may develop into endocrine tumours (gastric carcinoids) and may be divided into four distinct categories: type A, associated with chronic atrophic gastritis, type B, associated with the Zollinger-Ellison syndrome, type C, which is sporadic (Gough et al., 1994b; Kulke & Mayer, 1999; Soga, 1997), and type D, poorly differentiated endocrine carcinomas (Rindi et al., 1999). A fifth group can be added to this, ghrelin-secreting gastric carcinoids (Tsolakis et al., 2004). The majority of gastric carcinoids (~75%) are type A carcinoids; these patients have hypochlorhydria and hypergastrinaemia with ECL cell hyperplasia, and approximately 50% have associated pernicious anemia. Most of these tumours are small (less than 1 cm in diameter) and multifocal (Akerstrom, 1996); they are usually indolent, metastasising in 8%-23% (distant metastases in 3-5%) with a low overall mortality (Granberg et al., 1998). Between 5% and 10% of gastric carcinoids are associated with the Zollinger-Ellison syndrome; they occur almost exclusively in the context of Multiple Endocrine Neoplasia type 1 (MEN1), are multiple and may metastasise (5-10% of the cases) (Granberg et al., 1998). Type C gastric carcinoids (15-25%) are sporadic, usually solitary and greater
than 1 cm in diameter. These tumours are highly aggressive, the great majority being metastatic at diagnosis and associated with a high mortality rate (Akerstrom, 1996; Gough et al., 1994a; Rindi et al., 1996). One of the gastric endocrine hormones is ghrelin, synthesised in the ghrelin cells (previously known as X/A cells). Ghrelin is a 28 amino-acid hormone with growth hormone-releasing and appetite-inducing functions and it has been shown to be expressed in gastrointestinal stromal tumours (Ekeblad et al., 2006). A case-report has described a patient with a metastasising gastric neuroendocrine tumour which presented intense immunoreactivity for ghrelin and extremely high circulating levels of ghrelin (Tsikalis et al., 2004). Pancreatic tumours have also been described with excess ghrelin secretion (Corbetta et al., 2003).

In the last few years, patients with type A or B gastric carcinoids have increasingly been treated with somatostatin analogues. While treatment with proton-pump inhibitors is very effective in reducing hypergastrinaemia-induced gastric acid hypersecretion (Tomassetti et al., 2005), it does not improve the ECL cell hyperplasia. In a case-report of a patient with multiple type A gastric carcinoids, treatment with the long-acting somatostatin analogue octreotide-LAR for a period of 9 months induced normalisation of serum gastrin levels and permanent disappearance of the tumours (Prommegger et al., 2003). In another study (Fykse et al., 2004), five patients with hypergastrinaemia and gastric carcinoids were treated for a period of 1 year with monthly injections of octreotide-LAR; at the end of the study, although gastrin levels did not totally normalise, there was a significant reduction in tumour load, ECL cell density and normalisation of circulating chromogranin A levels, indicating a possible direct antiproliferative effect of the treatment. Furthermore, another study presented 3 patients suffering from Zollinger-Ellison syndrome who were treated with lanreotide
or octreotide for a period of 1 year, showing a significant reduction in the gastrin levels and no evidence of the tumours at the end of the study (Tomassetti et al., 2000a). Although the number of patients included in these studies is small, these results suggest that the somatostatin analogues have an important antiproliferative effect under some circumstances. However, there is little known regarding the effect of somatostatin analogues on cell proliferation in patients with gastric carcinoids type C or poorly differentiated endocrine carcinomas: in these tumours, such treatment may be considered only as palliative, reducing symptoms related to carcinoid syndrome.

[B] The role of somatostatin in the treatment of the midgut and hindgut carcinoid tumours

Midgut carcinoids constitute approximately 50% of all carcinoid tumours, the most common of the GEP NETs, affecting about 5-7 new patients per million population per year. These tumours are usually slow-growing; the clinical presentation may be related to pain, due to the tumour mass effect or to fibrosis in the mesentery. Another group of patients (around 10%-15%) suffer from the typical signs of the ‘carcinoid syndrome’ (watery diarrhoea, flushing, right-sided heart failure and bronchial constriction), which is related to the tumour hypersecretion of a variety of endocrine substances, the most frequent of which are serotonin (5-hydroxytryptamine) and the tachykinins (Kulke & Mayer, 1999). Since the majority of these patients have metastatic disease at the time of diagnosis, surgery is rarely curative and therefore medical treatment has to be considered (Oberg, 2002). These tumours frequently express somatostatin receptors (80%-100% of cases); SSTR2 is the most frequently
expressed (Reubi, 2004), and therefore somatostatin analogues are an important palliative tools for these patients.

**Somatostatin analogues as symptomatic treatment**

Many studies show that somatostatin analogues, at variable dosages (from 100μg twice a day to 200μg three times a day for octreotide, 10-30mg octreotide-LAR every 4 weeks or 30mg lanreotide every 10-14 days), may significantly improve symptoms such as diarrhoea, flushing or other manifestations of the carcinoid syndrome (between 38-88% in different studies); they may also significantly lower the levels of urinary-5HIAA (hydroxyindoleacetic acid), the metabolite of serotonin (Kvols et al., 1986; O'Toole et al., 2000; Oberg et al., 1991; Rubin et al., 1999b; Vinik et al., 1986; Wymenga et al., 1999).

A multicentre study of 33 patients with the carcinoid syndrome compared treatment with lanreotide (30mg im every 10 days) versus octreotide (200μg sc twice or thrice daily) in terms of patient preference and efficacy in controlling symptoms (O'Toole et al., 2000). No significant differences were found in terms of quality of life. Disappearance or improvement in flushes and diarrhoea occurred in 53.8% and 45.4% respectively, of the patients treated with lanreotide, while they were observed in 68% and 50% respectively, of those on octreotide. Both drugs were equally effective in reducing urinary 5HIAA levels and plasma serotonin levels. In a multicentre study on 71 patients with the carcinoid syndrome, 6 treatments of prolonged-release lanreotide Autogel were administered in various doses (60mg, 90mg or 120mg) depending on symptom response over a period of 6 months (Ruszniewski et al., 2004); 65% of the patients with flushing and 18% of diarrhoea patients achieved more than 50%
reduction of symptoms from baseline, with important reductions in urinary 5-HIAA and chromogranin A levels (24 and 38% respectively).

Another randomised double-blind trial which compared octreotide-LAR at 10, 20, and 30mg every 4 weeks with open-label sc octreotide every 8 hours for the treatment of carcinoid syndrome has shown that the efficacy of short-acting octreotide and of the long-acting octreotide-LAR was the same once plasma octreotide steady-state concentrations were achieved (Rubin et al., 1999a). Data from this study suggested that the starting dose for octreotide-LAR should be 20mg.

**Somatostatin analogue effect on tumour growth**

The antiproliferative effect of somatostatin analogues on the growth of the midgut carcinoids is largely unknown; overall, partial or complete responses were observed in fewer than 10% of the patients, while stabilisation of tumour growth was noticed in 24%-57% of the patients (Plockinger et al., 2004).

The administration of somatostatin analogues in regular doses produced stabilisation of tumour growth in 40%-50% of the patients in various studies (Arnold et al., 1996; Di Bartolomeo et al., 1996; Saltz et al., 1993), which persisted for varying periods of time (between 2 and 60 months). Tumour regression was partial in two out of 38 patients included in one of these studies (Di Bartolomeo et al., 1996), while no tumour regression was reported in the other two studies.

There are studies that indicate that using a higher than usual dose of somatostatin analogues may have a more prominent effect on tumour size. High-dose treatment with lanreotide (up to 12mg/day) produced tumour size reduction in 5% and stabilisation in 70% of the 19 patients included in one study (Eriksson et al., 1997). In another study in which 30 patients were treated with sc injections of 5mg lanreotide
three times a day for a period of one year, one complete and one partial remission were observed in patients with functional midgut NETs; in the same study, 11 patients had stable disease (36%) and 11 patients showed continuing tumour growth after 3-12 months of treatment (Faiss et al., 1999). In a study where biopsy specimens were taken before and during somatostatin analogue treatment the treatment with high-dose somatostatin analogues induced apoptosis in neuroendocrine tumours, while this was not found during treatment with low-dose somatostatin (Imam et al., 1997). According to these results, it is still hard to predict which patient will respond to the treatment in terms of tumour growth inhibition.

The effect of the combination of somatostatin analogues and interferon on tumour growth has been assessed in only a few studies, with variable results. One of these studies showed that this combination may be of benefit in patients where the usual octreotide treatment failed to achieve a biochemical and symptomatic control (Tiensuu Janson et al., 1992); another study indicates that this combination seemed to reduce the tumour progression compared with octreotide treatment alone, but without a significant effect on 5-year survival (Kolby et al., 2003). A third study suggested that the addition of alpha-interferon to octreotide showed antiproliferative efficacy in a subgroup of patients with advanced metastatic disease unresponsive to octreotide monotherapy, and prolonged survival was reported in the responder group (Frank et al., 1999). However, most published data do not support a major effect of interferons over and above that of somatostatin analogues.

Hindgut carcinoid tumours are rarely associated with a clinical syndrome; in such patients treatment with somatostatin analogues may be used for symptomatic relief, but there are no studies regarding their effect on tumour growth in hindgut tumours.
The role of somatostatin in the treatment of the pancreatic endocrine tumours

Endocrine pancreatic tumours are divided depending on their secretory ability into functioning or non-functioning tumours. The non-functioning tumours constitute the largest group, representing approximately 50% of the endocrine pancreatic tumours (Evans et al., 1993); following in incidence are the insulinomas (25%) (de Herder et al., 2006b) and gastrinomas (15%) (Roy et al., 2000), while the remaining 15% include VIP-omas (Soga & Yakuwa, 1998), glucagonomas (Chastain, 2001) and somatostatinomas (Soga & Yakuwa, 1999). Most of these tumours are sporadic, while about 15–30% are hereditary and appear in the context of MEN1 or von Hippel-Lindau syndromes.

Somatostatin receptors have been extensively mapped in different pancreatic tumours by means of autoradiography, reverse-transcription polymerase chain reaction, in situ hybridization and immunohistochemistry. SSTR1, 2, 3 and 5 are usually expressed in the majority of pancreatic NETs, the exception being the benign insulinoma in which the SSTR2 is less expressed (Janson & Oberg, 2003). Another study examining 81 functioning and non-functioning GEP NETs showed that the vast majority expressed SSTR1, 2, 3 and 5, while SSTR4 was detected only in a small minority (Papotti et al., 2002). Pancreatic insulinomas had heterogeneous SSTR expression, while 100% of somatostatinomas expressed SSTR5 and 100% gastrinomas and glucagonomas expressed SSTR2.

The role of somatostatin analogues in the treatment of insulinomas

Insulinoma is a rare but an important cause of endogenous hypoglycaemia, occurring with an incidence of about 1/million population per year (Service et al., 1991).
Somatostatin analogue treatment can improve (inhibition of insulin release) or worsen (profound suppression of counter-regulatory hormones GH and glucagon) the symptoms associated with hypoglycaemia (Maton, 1993). Therefore, treatment has to be started in a hospital setting, using a gradually increasing dose escalation of the drug, and frequent monitoring of blood glucose levels. Recently, a study of 17 patients with insulinoma assessed the efficacy of octreotide on hypoglycaemia and its relation to a positive octreoscan and with immunostaining with anti-SSTR2 and anti-SSTR5 antibodies (Vezzosi et al., 2005). Octreotide was effective in the control of hypoglycaemia in more than 50% of the patients, and a positive subcutaneous short octreotide test (100μg octreotide sc in fasting patients, with improvement in hypoglycaemia) was a better marker of responsive patients than positive scintigraphy. The treatment was effective in all SSTR2-positive patients and in a few SSTR2 negative ones, while no relation between treatment effectiveness and the expression of SSTR5 was observed. These results are in concordance with other case reports and smaller series of insulinoma patients reported in the literature (Hearn et al., 1988a; Tanaka et al., 2000; Verschoor et al., 1986; von Eyben et al., 1994). Given the fact that surgical excision is the definitive treatment of insulinoma, there are no clear data in the literature regarding the potential antiproliferative effect of the somatostatin analogues on these tumours.

We have conducted a study regarding the effects of somatostatin analogues on cell proliferation in the rat-derived insulinoma cell line (INS1). Our preliminary data show that octreotide has a significant inhibitory effect on cell proliferation, as assessed by cell counting and MTS assay, and on phosphorylation states of a number of proteins in the PI3K/Akt/mTOR pathway (Franchi et al., 2007).
The role of somatostatin analogues in the treatment of gastrinomas

Gastrinomas are the second most frequent functional endocrine tumours of the pancreas, occurring either in a sporadic form or, in up to 25%, in the context of MEN1 syndrome (Jensen, 1996). The effects of gastric acid hypersecretion dominate the clinical picture of the gastrinomas; therefore, proton pump inhibitors are currently the therapy of choice for the control of gastric-acid associated symptoms (Metz et al., 1993). Few data are available regarding the role of somatostatin analogues in the treatment of gastrinomas. In a study of 15 malignant gastrinoma patients (Shojamanesh et al., 2002), treatment with octreotide-LAR was administered with a primary goal of assessing its effect on tumour size; in about 50% of these patients, octreotide had an antiproliferative effect, including 1 patient with tumour regression and another 7 patients with tumour stabilisation (for a mean period of 25 months). An important observation of this study was that patients with slow-growing tumours were more likely to respond to this treatment; therefore, the authors recommended that octreotide treatment should replace chemotherapy as the standard treatment for these patients. Recently, the high expression of somatostatin receptors on gastrinomas has been considered as an opportunity to administer radiolabeled somatostatin analogues, in order to achieve a cytotoxic effect (\(^{111}\)In-labelled analogues, \(^{90}\)yttrium or \(^{177}\)lutetium) (Jensen, 2004).

The role of somatostatin analogues in the treatment of glucagonomas

Glucagonomas are rare slow-growing pancreatic tumours, originating in the \(\alpha\)-cells of the pancreas; the majority are sporadic, and rarely they may be associated with
familial syndromes (MEN1 or familial adenomatous polyposis) (Chastain, 2001). Somatostatin analogue treatment may be indicated in glucagonoma patients for alleviating the symptoms related to the characteristic skin rash (necrolytic migratory erythema) or diarrhoea (Casadei et al., 1999; Tomassetti et al., 2000b; Wermers et al., 1996). There are no data available on their SSTR expression patterns.

The role of somatostatin analogues in the treatment of somatostatinomas

Somatostatinomas are very rare tumours, originating either in pancreas or in the small intestine (Soga et al., 1990; Soga & Yakuwa, 1999); the symptoms are usually related to somatostatin hypersecretion (hyperglycaemia, cholelithiasis, diarrhoea and steatorrhoea, hypochlorhydria) or to the mass effect (Soga & Yakuwa, 1999). It is an interesting concept to treat patients with elevated somatostatin levels and symptoms related to the high somatostatin levels with a somatostatin analogue. In a study of three patients with metastatic somatostatinomas, octreotide treatment was shown to be effective in reducing plasma levels of somatostatin and improving the related symptoms; an octreoscan detected somatostatinomas tumour lesions in all three patients studied (Angeletti et al., 1998).

The role of somatostatin analogues in the treatment of VIP-omas

VIP-omas are rare pancreatic endocrine tumours which secrete vasoactive intestinal polypeptide (VIP). VIP is a potent stimulant of adenylate cyclase, which will cause hypersecretion of water and electrolytes by the intestinal mucosa, contributing to a typical clinical syndrome (Verner-Morrison syndrome) characterised by watery diarrhoea, hypokalaemia, achlorhydria and metabolic acidosis (Bloom et al., 1973; Schwartz et al., 1974). 50% of these tumours are malignant and the mortality rate may
be as high as 30% due to the serious metabolic consequences of the syndrome. Intravenous fluid and electrolyte replacement is essential, together with octreotide, which will control symptoms promptly in more than 90% of patients (O'Dorisio et al., 1989). A recent retrospective review described four cases of VIP-oma in which octreotide was very successful as an adjuvant therapy for symptom control and for reducing the serum elevated VIP levels (Ghaferi et al., 2007), improving the diarrhoea and the electrolyte imbalance. Corticosteroids may be used in patients not responding to somatostatin analogues.

**Somatostatin analogues and non-functioning endocrine pancreatic tumours**

The place of somatostatin analogues in the treatment of these tumours is unclear, as few studies have been published in these patients. A prospective multicentre trial investigated the octreotide effects on tumour growth after 1 year of treatment in 103 metastatic GEP NETs patients and included 15 patients with diagnosed non-functional pancreatic tumours (Arnold et al., 1996); in this subgroup, tumour growth stabilised in only 3 patients, while in another 8 patients the tumour progressed (the outcome of the remaining 4 patients was not clear). Recently, a case report described that octreotide-LAR was useful in achieving tumour regression in one and in preventing tumour progression in another patient diagnosed with a metastatic non-functioning neuroendocrine pancreatic tumour (Koehler et al., 2007).

**II. The role of somatostatin analogues in the diagnosis and treatment of other neuroendocrine tumours**

*Medullary thyroid carcinoma (MTC)*
MTC is a rare tumour of the thyroid (3%-10% of all thyroid carcinomas) originating in the parafollicular C cells. This tumour can be sporadic, while in about 25% it may be hereditary, as part of the multiple endocrine neoplasia syndrome 2 (MEN2) type A or type B, or as an isolated familial form (Familial MTC) (Marsh et al., 1995). MTC may synthesise and secrete calcitonin in high amounts, as well as other peptides such as carcinoembryonic antigen (CEA), neuron specific enolase (NSE), chromogranin A or ACTH resulting in diarrhoea, facial flushing or Cushing’s syndrome (Kebebew et al., 2000; Raue, 1998). Total thyroidectomy with central lymph node dissection is the initial and the only potentially curative treatment of choice (Giuffrida & Gharib, 1998).

The distribution of somatostatin receptors (SSTR1-5) in MTC was analysed by immunohistochemistry in a large retrospective study including 51 MTC specimens; the results were correlated with expression of somatostatin peptide, tumour pathology and clinical outcome (Papotti et al., 2001). 49% of the tumours were positive for SSTR1, 43% for SSTR2, 47% for SSTR3, 4% for SSTR4, and 57% for SSTR5, with 75% of the specimens expressing the octreotide-sensitive receptor subtypes (SSTR2 and SSTR5) and even higher percentage potentially expressing pasireotide (SOM230)-sensitive SSTRs. In this study, no correlation between SSTR1-5 expression and age, sex, tumour size or staging, histological type or clinical outcome was found.

Studies assessing the effect of somatostatin analogues in the treatment of symptomatic MTC are limited and controversial. In one study, this treatment produced a significant improvement in symptoms such as diarrhoea, weight loss or malaise in all of the three patients with metastatic MTC which were included, with a parallel decrease in the calcitonin and CEA levels (Mahler et al., 1990). In another study, 14 post-
thyroidectomy metastatic MTC patients were treated with continuous subcutaneous
infusion of 500µg/day of octreotide, for 90 days, in order to assess the effect of the
treatment on tumour regression (Modigliani et al., 1992). Continuous infusion of
octreotide did not induce any morphological improvement or a significant decrease in
calcitonin levels; in 4 patients calcitonin levels fell during treatment (between 15%
and 50%), while in 9 patients calcitonin increased (from 22% to 130%) after
cessation of therapy. In patients with advanced metastatic disease, the administration
of octreotide combined with interferon was studied; in a study of 8 patients with
advanced MTC, patients received octreotide (at a starting dose of 150µg/day sc for 6
months, followed by a dose of 300µg/day sc for another 6 months) combined with
rIFN-alpha-2b (at a dose of 5 million IU/day im 3 times a week, for 12 months)
(Lupoli et al., 1996); while significant symptomatic improvement was observed in
some of the treated patients (diarrhoea, in four patients, and flushing, in one), no
significant changes in the size of metastases were observed. A maximum decrease of
calcitonin was reached after 3 months in 4 patients, while in all patients the CEA
levels decreased during treatment. In another study, disease stabilisation was achieved
in three patients and minor tumour regression in two patients out of the 7 patients
included (Vitale et al., 2000).

Radionuclide therapy using somatostatin analogues has been used occasionally in
these patients: a few patients with MTC have received $^{111}$In-octreotide or $^{90}$Y-
lanreotide in the MAURITIUS trial (Virgolini et al., 2002) and the initial results were
encouraging, suggesting that more prospective studies are needed. To summarise,
somatostatin analogues may produce symptomatic improvement in some patients with
metastatic MTC, with a transient effect on the hormonal levels; however, their effect
on tumour growth and proliferation is still unclear.
Bronchial carcinoid tumours

Bronchial carcinoid tumours belong to the foregut carcinoids, accounting for about 2.5% of all pulmonary neoplasms and for 12-15% of carcinoid tumours overall. They originate from the neuroendocrine cells of bronchial mucosa, presenting a wide range of clinical and biological behaviour; this includes their potential to synthesise and secrete peptide hormones, particularly ACTH, serotonin, somatostatin and bradykinin. Neuroendocrine lung tumors were previously subdivided into typical and atypical carcinoids (Arrigoni et al., 1972), and small cell lung carcinomas, but several other classifications have later been proposed (Capella et al., 1995; Travis et al., 1998; Warren & Gould, 2002; Warren et al., 2006), and a fourth category, termed large cell neuroendocrine carcinomas, was defined; the major WHO morphological categories of lung neuroendocrine tumours include low-grade typical carcinoid (TC), intermediate-grade atypical carcinoid (AC), the high grade small cell carcinoma (SCLC) and large cell neuroendocrine carcinoma (LCNEC) (Beasley et al., 2005).

Neuroendocrine lung tumours are characterised structurally by the presence of dense core granules, and immunohistochemically by the production of small polypeptides. Many of the patients with bronchial carcinoids (13%–51%) are asymptomatic, the tumour being detected on routine chest X-ray. Presenting symptoms may include cough, hemoptysis, dyspnoea, wheezing, chest pain and recurrent pulmonary infections; the carcinoid syndrome (with flushing, diarrhoea, wheezing and elevated urinary 5-HIAA) is infrequent, occurring in 2%–12% of the patients (Dusmet & McKneally, 1994; Soga et al., 1999a). Liver metastases are detected in most patients displaying the carcinoid syndrome (Davila et al., 1993; Dusmet & McKneally, 1994).
An atypical carcinoid syndrome (with severe generalised flushing, swelling, lacrimation, asthma and diarrhoea), due to histamine secretion, may be observed. Ectopic Cushing’s syndrome, due to secretion of ACTH or CRH, is seen in 2%–6% of bronchial carcinoid patients (Soga et al., 1999b).

Regarding the expression of SSTRs, a study that assessed the expression of SSTR2A immunoreactive cells in normal lung tissue using a highly specific SSTR2A antibody (R2-88) demonstrated only rare SSTR2A positive cells in bronchi and bronchioles, which could represent stem/progenitor cells (Gugger et al., 2004). In another study in which several methods (e.g., receptor binding, in situ hybridisation, and immunohistochemistry) were combined and correlated SSTR2A in different human tumours, demonstrated the expression of these receptors in some of the bronchial carcinoids (Reubi et al., 1998). The analysis of tumor tissue from 5 patients with bronchial carcinoid tumors using polyclonal antibodies directed against SSTR2 and consequently immunohistochemistry demonstrated that only one of these patients stained positive with the SSTR2 antibodies, whereas the other four were negative (Janson et al., 1998). This result correlated well with the uptake of the tumour on octreoscan: the only patient with a positive stain at immunohistochemistry also showed uptake at scintigraphy. By contrast, it was showed that small cell lung carcinomas often possess somatostatin receptors (Reubi et al., 1990; Reubi et al., 1994).

In a study of 28 patients with histologically-confirmed bronchial carcinoids who underwent octreoscan examination, and had their results compared with CT, MRI and bone scan, 20 patients (71%) had octreoscan-positive tumours, including 2/5 patients with ectopic ACTH secretion and 8/9 patients with carcinoid syndrome. The primary tumour was octreoscan-positive in 13/16 patients and could be detected on CT in
15/16 patients. The authors concluded that in patients with bronchial carcinoids, octreoscan is less sensitive for detection of the primary tumour and liver metastases than CT, and the conventional bone scan is more effective than the octreoscan for identification of bone metastases (Granberg et al., 2003). Nevertheless, the octreoscan may be useful in the follow-up of patients with somatostatin-receptor positive bronchial carcinoid tumours and should be performed in all these patients prior to attempts at curative surgery. There are several case reports in which the octreoscan identified the primary tumour in patients with occult ectopic Cushing’s syndrome (Carretta et al., 1997; Mansi et al., 1997; Philipponneau et al., 1994). Octreotide has mainly symptomatic effects in patients with bronchial carcinoids, while its effect on tumour growth is controversial. In a study of 31 patients with metastatic pulmonary carcinoids (Granberg et al., 2001), somatostatin analogues given as single drug treatment were associated with progressive disease; the combination of α-interferon and octreotide produced efficient symptomatic relief, but stabilised the tumour growth in only 15% of the cases. However, in another study, the administration of octreotide at a daily dosage of 1500μg sc controlled the symptoms associated with carcinoid syndrome in all patients and induced reduction/complete resolution of the liver metastases in 3 out of the 7 patients included (Filosso et al., 2002). In patients with ectopic Cushing’s syndrome due to ACTH secretion from lung carcinoids, administration of the somatostatin analogue octreotide was shown to be effective in reducing the circulating ACTH levels (Hearn et al., 1988b).

*Thymic carcinoid tumours*
The thymus is one of the rarest sites for the development of neuroendocrine tumours and they usually carry a poor prognosis. Eight cases of thymic carcinoids were first described in 1972 as a different entity from thymic carcinomas (Rosai & Higa, 1972) and ~150 cases have been reported since. Rarely, these tumours may appear in association with multiple endocrine neoplasia type 1 (MEN1) (Rosai et al., 1972). Thymic carcinoids are frequently metastatic, have a poor outcome and are commonly associated with ectopic ACTH production, but not with the carcinoid syndrome (Moran & Suster, 2000).

Regarding SSTR expression by these tumours, the literature is limited; in one study, none of the 12 thymic carcinoid specimens analysed stained positively for somatostatin receptors (Tiffet et al., 2003), while expression of somatostatin receptors was demonstrated in another study of a thymic carcinoid tumour, which was subsequently visualised on somatostatin receptor scintigraphy (Nilsson et al., 1998). The usefulness of octreoscanning as a diagnostic technique in these patients was confirmed in 4 of 7 patients with distant intra- and extrathoracic metastases involving lymph nodes, liver, bone, skin, and adrenal glands (Ferolla et al., 2005). However, in another study, the octreoscan was unable to detect the development of bone metastases in two out of the 7 patients with metastatic thymic carcinoids included (Gibril et al., 2003). There are a number of case reports in which somatostatin analogues were efficient in the detection and symptomatic relief in patients with thymic carcinoid tumours associated with ectopic growth hormone-releasing hormone (GHRH) (Boix et al., 2002) or ectopic ACTH secretion (Matejka et al., 1996). The efficacy of somatostatin receptor scintigraphy in the detection of small thymic lesions has not been completely established. There are no data in the literature regarding the effect of somatostatin analogues on the growth of thymic carcinoids.
Ovarian carcinoids

These are rare tumours (0.52%–1.7% of ovarian tumours in different series) which usually present with either pain in the pelvic area or pain with defaecation (Davis et al., 1996). Some of these tumours are cystic teratomas with a more benign course, fewer incidences of regional and hepatic metastases and a 5-year survival of almost 100%, while others have a 5-year survival rate of about 84%. The carcinoid syndrome is present in approximately 30% of patients, while ectopic ACTH secretion inducing the clinical picture of Cushing’s syndrome has also been reported (Schlaghecke et al., 1989).

The expression of SSTR specifically by ovarian carcinoids is unclear; however, in a study in which 47 different ovarian tumour specimens were analysed (Schulz et al., 2002), 18 tumours (38%) revealed no somatostatin receptor immunoreactive staining, while 14 (30%) expressed more than one somatostatin receptor subtype; this was independent of patient age, diagnosis and histological grade.

The treatment of choice for these tumours is surgical excision; there are a limited number of published case reports in which octreotide was used as a symptomatic therapy, for alleviating symptoms associated with carcinoid syndrome, or intraoperatively in patients with carcinoid associated right heart failure (Vergani et al., 1998; Watson et al., 1990).

There are no data in the literature regarding the antiproliferative effect of somatostatin analogues in the treatment of these tumours.

Phaeochromocytomas and paragangliomas
Pheochromocytomas and paragangliomas are NETs arising from chromaffin cells and may occur in sporadic or familial forms (associated with MEN2A or 2B, von Hippel-Lindau syndrome, Neurofibromatosis 1, Carney’s triad, or mutations of succinic dehydrogenase subunits C, D and particularly B) (Goldstein et al., 1999; Astuti et al., 2003; Astuti et al., 2004; Mhatre et al., 2004; Neumayer et al., 2007). Phaeochromocytomas are chromaffin cell tumours originating in the adrenal medulla (Shapiro & Fig, 1989), while paragangliomas derived from the paraganglia (sympathetic, localised mainly in the retroperitoneum and thorax, or parasympathetic, occurring in the area of the aortic arch, neck, and skull base). Very approximately, about 10% of chromaffin cell tumours are malignant, 10% are familial, 10% are not associated with hypertension, 10% are extra-adrenal, 10% are bilateral, and 10% occur in children (Schlumberger et al., 1992) although recent data suggest that the proportion of apparently sporadic tumours associated with germline mutations may be as high as 30% (Cascon et al., 2004; Castellano et al., 2006). The catecholamines (epinephrine/adrenaline, norepinephrine/noradrenaline and dopamine) are the main secretory products of chromaffin cells. A number of hormones have been described in patients with functioning catecholamine secreting tumours: secretion of ACTH, inducing Cushing’s syndrome; substance P, tachykinins and histamine inducing hypotension; VIP and calcitonin gene-related peptide (CGRP) which may produce flushing (Bravo & Tagle, 2003).

In a study which assessed the SSTR expression in 10 phaeochromocytomas, no SSTR5 expression was found, while SSTR1 was present in nearly all of these tumours (Ueberberg et al., 2005). SSTR protein expression, including staining pattern, distribution and subcellular localisation of receptor subtypes, was evaluated in another study including 52 phaeochromocytomas (Mundschenk et al., 2003).
Although the vast majority of tumours (90%) showed positive immunohistochemical staining for SSTR3, immunoreactive SSTR2A was seen only in 13 tumours (25%). All other somatostatin receptor subtypes were less frequently detected. Interestingly, a dissociation between the SSTR positive expression followed by a positive response to somatostatin analogues in vitro, and a negative octreoscan in vivo, was described (Zatelli et al., 2003), indicating that somatostatin analogues may be helpful in the treatment of phaeochromocytomas even when the octreoscan is negative.

Because chromaffin cell tumours often express SSTRs, the octreoscan may be used for the tumour localisation, particularly in cases of $^{123}$I-MIBG-negative lesions (Kaltsas et al., 2001).

Following the stabilisation of the clinical symptoms with specific antihypertensive treatment, surgical excision of the tumour should be performed in order to obtain disease-free, long-term survival (Bravo, 2002). Short-term or long-term administration of somatostatin analogues has not been shown to be of any benefit, although rarely biochemical responses have been observed (Kopf et al., 1997), being capable of lowering the levels of norepinephrine, but with no consistent effect on blood pressure (Invitti et al., 1993; Lamarre-Cliche et al., 2002). However, another study demonstrated that sometimes octreotide may control the blood pressure before surgery in some patients with phaeochromocytoma-induced uncontrolled hypertension (Koriyama et al., 2000). Rarely, malignant phaeochromocytomas may be octreotide - but not MIBG - avid; in such cases therapy with octreotide could be of value (van der Harst et al., 2001); occasionally, disease stabilisation has been reported in a few patients with malignant chromaffin cell tumours treated with radionuclide somatostatin analogues, such as $^{111}$In-octreotide and $^{90}$Y-octreotide (DOTATOC) (Valkema et al., 2002).
III. New therapies in NETs

Pasireotide (SOM230) and other somatostatin analogues

The natural compound somatostatin is capable to bind with a high affinity to all SSTR subtypes (SSTR1, 2, 3, 4, and 5), while its synthetic analogues have only limited affinity, binding mainly to SSTR2, with lesser affinity for SSTR3 and SSTR5 (Patel, 1999). Therefore, new somatostatin analogues are being studied: SOM230 (pasireotide), which is discussed in more detail elsewhere in this volume, is a new “universal” or “pan-receptor” somatostatin analogue, which possess a high affinity for SSTR1, 2, 3, and 5 subtypes, being under evaluation in phase I-III trials (Bruns et al., 2002; Lamberts et al., 2002b; Weckbecker et al., 2002). Its receptor binding profile is 30- to 40-times higher for SSTR1 and SSTR5 than octreotide. In a phase II open-label, multicentre study including 21 patients with metastatic carcinoid tumours whose symptoms (diarrhoea and flushing) were refractory to octreotide-LAR, pasireotide at dosages between 450-1200µg twice a day effectively controlled symptoms in one-third of these patients and was generally well tolerated (Kvols et al., 2005).

It has been shown that subtypes of somatostatin and dopamine receptors may form homo- and hetero-dimers at the membrane level, and that this receptor “association” may be induced by addition of either dopamine or somatostatin. The development of somatostatin receptor subtype-specific analogues or chimeric analogues binding to SSTR2, SSTR5 and dopamine 2 receptors has demonstrated some promising clinical results. Recently, a number of new interesting compounds (subtype selective analogues and antagonists, as well as bi-specific and hybrid somatostatin/dopamine compounds), have been developed (Ferone et al., 2007). The effects of these chimeric
molecules have been studied in animal and human cell lines, and also in primary cultures from human tumours. Their activity is complex and heterogeneous, and further studies are needed to understand their biological effects.

*Radiolabelled somatostatin analogues and the peptide receptor radionuclide therapy (PRRT)*

Somatostatin receptor targeted radiotherapy represents a new advance in the treatment of NETs. It is based on the presence of SSTRs in a higher density in these tumours (compared with the normal surrounding parenchyma), and on their ability to form a receptor-ligand complex, permitting therefore the internalisation and the accumulation of the radiopharmaceutical inside the tumour.

PRRT was performed initially using indium-111, with only a few objective responses-rates (Fjalling et al., 1996; Kwekkeboom et al., 2005). The development of radio-metal labelling chelators, such as DOTA (1,4,7,10-tetrazacyclo-dodecane-N,N0,N00,N000-tetraacetic acid), which may be combined with metal ions (such as gallium, yttrium or lutetium), has allowed new therapeutic applications (Heppeler et al., 2000). In a phase II study which evaluated the tumour response to targeted irradiation with the radiolabelled somatostatin analogue $^{90}$Y-DOTATOC in 41 patients with GEP NET and bronchial tumours, the overall response rate was 24% (36% for endocrine pancreatic tumours) (Waldherr et al., 2001). Complete remissions were observed in 2% (1 of 41), partial remissions (PR) in 22% (9 of 41), a minor response in 12% (5 of 41), stable disease in 49% (20 of 41) and progressive disease in 15% (6 of 41). The median duration of response had not been reached at 26 months, and the two-year survival time was $76 \pm 16\%$. There was a significant reduction of symptoms (83% from the patients suffering from the malignant carcinoid syndrome),
and the treatment was well tolerated. Promising results were obtained using ([177Lu]octreotate) (Kwekkeboom et al., 2005), in a study of 103 patients with NETs, mostly GEP tumours: complete remission in three patients (2%), partial remission in 32 patients (26%), a minor response (tumor diameter decrease of 25% to 50%) in 24 patients (19%), stable disease in 44 patients (35%), and progressive disease in 22 patients (18%). Higher remission rates were positively correlated with high uptake on pre-therapy somatostatin receptor imaging and a limited number of liver metastases, whereas progressive disease was significantly more frequent in patients with a low performance score and extensive disease. Median time to progression in 103 patients who either had stable disease or tumour regression was more than 36 months. In a preclinical study using the combination of 90Y- and 177Lu-labeled analogs (de Jong et al., 2005), this combination had superior antitumor effects when compared with either 90Y- or 177Lu-analog alone in animals bearing tumours of various sizes. In the future, treatment with both 90Y- and 177Lu coupled to a somatostatin analogue might come into clinical trials, as 177lutetium may be more effective for smaller tumours whereas 90yttrium may be more effective for larger tumours (Oberg & Eriksson, 2005; Chan & Kulke, 2007).

The use of PRRT appears to be an important progress in the treatment of these tumours; nevertheless, there are still unresolved questions, such as which is the best time for its administration, and what is the most appropriate radioligand/combination to be useful in a certain patient.

Conclusions

Although the somatostatin analogues have been shown to be very useful for the symptomatic and biochemical improvement in patients with NETs, specifically
functional GEP tumours, their antiproliferative effects are less impressive. A certain proportion of patients achieve tumour growth stabilisation, while reduction in the size of the tumour is rare. Therefore, prospective studies including large number of patients and using higher dose, more potent somatostatin analogues or analogues with wider SSTR profile are needed for assessing the real antiproliferative ability of these drugs.
Reference List


